Evidence map›Paper›PMID 36090164›Full record

ArticleFrontiers in veterinary science2022

Development of anti-Crimean-Congo hemorrhagic fever virus Gc and NP-specific ELISA for detection of antibodies in domestic animal sera.

Sandra Belij-Rammerstorfer, Georgina Limon, Emmanuel A Maze, Kayleigh Hannant, Ellen Hughes, Simona R Tchakarova, Tsviatko Alexandrov, Blandina T Mmbaga, Brian Willett, George Booth and 12 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in veterinary science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Vector-borne diseases-knowledge maps.EFSA journal. European Food Safety Authority · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 8 institutions in 3 countries.

Sandra Belij-RammerstorferNuffield Department of Medicine, The Jenner Institute, University of Oxford, Oxford, United Kingdom.
Georgina LimonThe Pirbright Institute, Woking, United Kingdom.
Emmanuel A MazeThe Pirbright Institute, Woking, United Kingdom.
Kayleigh HannantThe Pirbright Institute, Woking, United Kingdom.
Ellen HughesMedical Research Council (MRC)-University of Glasgow Centre for Virus Research (CRV), Glasgow, United Kingdom.
Simona R TchakarovaBulgarian Food Safety Agency, Sofia, Bulgaria.
Tsviatko AlexandrovBulgarian Food Safety Agency, Sofia, Bulgaria.
Blandina T MmbagaKilimanjaro Clinical Research Institute (KCRI), Kilimanjaro Christian Medical Centre, Moshi, Tanzania.
Brian WillettMedical Research Council (MRC)-University of Glasgow Centre for Virus Research (CRV), Glasgow, United Kingdom.
George BoothThe Pirbright Institute, Woking, United Kingdom.
Nicholas A LyonsThe Pirbright Institute, Woking, United Kingdom.
Natalie BakerResearch and Evaluation, UK Health Security Agency, Porton Down, United Kingdom.
Kelly M ThomasResearch and Evaluation, UK Health Security Agency, Porton Down, United Kingdom.
Daniel WrightNuffield Department of Medicine, The Jenner Institute, University of Oxford, Oxford, United Kingdom.
Jack SaundersNuffield Department of Medicine, The Jenner Institute, University of Oxford, Oxford, United Kingdom.
Clare BrowningThe Pirbright Institute, Woking, United Kingdom.
Ginette WilsdenThe Pirbright Institute, Woking, United Kingdom.
Miles CarrollPandemic Science Institute, Wellcome Centre for Human Genetics, Nuffield Department of Medicine, Oxford University, Oxford, United Kingdom.
Roger HewsonResearch and Evaluation, UK Health Security Agency, Porton Down, United Kingdom.
Bryan CharlestonThe Pirbright Institute, Woking, United Kingdom.
Teresa LambeNuffield Department of Medicine, The Jenner Institute, University of Oxford, Oxford, United Kingdom.
Anna B LudiThe Pirbright Institute, Woking, United Kingdom.
The Pirbright Institute · GBUK Health Security AgencyUniversity of Oxford · GBBulgarian Food Safety Agency · BGJenner Institute · GBKilimanjaro Christian Medical Centre · TZMedical Research Council · GBMRC University of Glasgow Centre for Virus Research · GB

Funding

Biotechnology and Biological Sciences Research Council BBS/E/I/00007036
6 · The paper itself

Abstract

Crimean-Congo hemorrhagic fever (CCHF) is a priority emerging disease. CCHF, caused by the CCHF virus (CCHFV), can lead to hemorrhagic fever in humans with severe cases often having fatal outcomes. CCHFV is maintained within a tick-vertebrate-tick cycle, which includes domestic animals. Domestic animals infected with CCHFV do not show clinical signs of the disease and the presence of antibodies in the serum can provide evidence of their exposure to the virus. Current serological tests are specific to either one CCHFV antigen or the whole virus antigen. Here, we present the development of two in-house ELISAs for the detection of serum IgG that is specific for two different CCHFV antigens: glycoprotein Gc (CCHFV Gc) and nucleoprotein (CCHFV NP). We demonstrate that these two assays were able to detect anti-CCHFV Gc-specific and anti-CCHFV NP-specific IgG in sheep from endemic CCHFV areas with high specificity, providing new insight into the heterogeneity of the immune response induced by natural infection with CCHFV in domestic animals.

Indexed as

antibody responseCCHFV GcCCHFV NPCrimean-Congo hemorrhagic feverdomestic animalsELISA

Identifiers

PMID36090164
PMCPMC9454098
OpenAlexW4293051592

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.